Talk to me bout the var bridge?

[Bull]

I was not talking about HTPA, I was taking about liver toxic. Thanks anyway.

[Juice Authority]

Originally posted by Bull
I was not talking about HTPA, I was taking about liver toxic. Thanks anyway.

Wrong again Einstein! You really need to take your own advice and get your facts straight! LOL!!!

http://www.medibolics.com/oxandrin2.htm

Heard in Geneva:
Oxandrin May Cause Liver Toxicity
by Michael Mooney (Original article in issue #7, October, 1998. Updated July, 2001)

(See also Dr. Donald Abrams review in The AIDS Reader March, 2001;11(3)

While Oxandrin is promoted as being non-toxic to the liver, the truth is Oxandrin is a 17-alpha alkylated oral anabolic steroid so it has the potential to burden the liver, just like any other oral 17-alpha alkylated steroid. We have questioned that its potential for liver toxicity would be enhanced when it is used with other liver-challenging drugs like protease inhibitors and other standard AIDS medications, or with higher dosages. We have an answer.


Int J Obes Relat Metab Disord 1995 Sep;19(9):614-24

Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men.

Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C, Tulley R.

Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808-4124, USA.

OBJECTIVE: To compare the effects of testosterone enanthate (TE), anabolic steroid (AS) or placebo (PL) on regional fat distribution and health risk factors in obese middle-aged men undergoing weight loss by dietary means. DESIGN: Randomized, double-blind, placebo-controlled clinical trial, carried out for 9 months with primary assessments at 3 month intervals. Due to adverse blood lipid changes, the AS group was switched from oral oxandrolone (ASOX) to parenteral nandrolone decaoate (ASND) after the 3 month assessment point. SUBJECTS: Thirty healthy, obese men, aged 40-60 years, with serum testosterone (T) levels in the low-normal range (2-5 ng/mL). MAIN OUTCOME MEASURES: Abdominal fat distribution and thigh muscle volume by CT scan, body composition by dual energy X-ray absorptiometry (DEXA), insulin sensitivity by the Minimal Model method, blood lipids, blood chemistry, blood pressure, thyroid hormones and urological parameters. RESULTS: After 3 months, there was a significantly greater decrease in subcutaneous (SQ) abdominal fat in the ASOX group compared to the TE and PL groups although body weight changes did not differ by treatment group. There was also a tendency for the ASOX group to exhibit greater losses in visceral fat, and the absolute level of visceral fat in this group was significantly lower at 3 months than in the TE and PL groups. There were significant main effects of treatment at 3 months on serum T and free T (increased in the TE group and decreased in the ASOX group) and on thyroid hormone parameters (T4 and T3 resin uptake significantly decreased in the ASOX group compared with the other two groups). There was a significant decrease in HDL-C, and increase in LDL-C in the ASOX group, which led to their being switched to the parenteral nandrolone decanoate (ASND) after 3 months. ASND had opposite effects on visceral fat from ASOX, producing a significant increase from 3 to 9 months while continuing to decrease SQ abdominal fat. ASND treatment also decreased thigh muscle area, while ASOX treatment increased high muscle. ASND reversed the effects of ASOX on lipoproteins and thyroid hormones. The previously reported effect of T to decrease visceral fat was not observed, in fact, visceral fat in the TE group increased slightly from 3 to 9 months, although SQ fat continued to decrease. Neither TE nor AS treatment resulted in any change in urologic parameters. CONCLUSIONS: Oral oxandrolone decreased SQ abdominal fat more than TE or weight loss alone and also tended to produce favorable changes in visceral fat. TE and ASND injections given every 2 weeks had similar effects to weight loss alone on regional body fat. Most of the beneficial effects observed on metabolic and cardiovascular risk factors were due to weight loss per se. These results suggest that SQ and visceral abdominal fat can be independently modulated by androgens and that at least some anabolic steroids are capable of influencing abdominal fat.

[Juice Authority]

Originally posted by Bull
I was not talking about HTPA, I was taking about liver toxic. Thanks anyway.

Also, Anavar is as liver toxic as any other 17aa roid. AIDS patients got problems with 20mg ed (they are running it for life without a break though)


Clin Endocrinol (Oxf) 1997 Feb;46(2):209-16

Effect of low dose oxandrolone and testosterone treatment on the pituitary-testicular and GH axes in boys with constitutional delay of growth and puberty.
Crowne EC, Wallace WH, Moore C, Mitchell R, Robertson WH, Holly JM, Shalet SM.
Department of Endocrinology, Christie Hospital Trust, Manchester, UK.
OBJECTIVE: To investigate the effect of low dose oxandrolone and testosterone on the pituitary-testicular and GH-IGF-I axes. DESIGN: Prospective double-blind placebo-controlled trial. PATIENTS: Sixteen boys with constitutional delay of growth and puberty (CDGP) with testicular volumes 4-6 ml were randomized to 3 months treatment: Group 1 (n = 5), daily placebo: Group 2 (n = 5), 2.5 mg oxandrolone daily or Group 3 (n = 6), 50 mg testosterone monthly intramuscular injections with assessment (growth, pubertal development and overnight hormone profiles) at 0, 3, 6 and 12 months. MAIN OUTCOME MEASURES: LH and GH profiles (15-minute samples) were analysed by peak detection (Pulsar), Fourier transformation and autocorrelation. Testosterone levels were measured hourly and insulin, SHBG, IGF-I, and IGFBP-3 levels at 0800 h. Statistical analysis was by multivariate analysis of variance for repeated measures. RESULTS: LH and testosterone parameters increased significantly with time in all 16 (LH AUC, P < 0.001; peak amplitude, P = 0.02; number of peaks, P = 0.02; testosterone AUC, P = 0.02; morning testosterone, P = 0.002). In Group 2, however, LH and testosterone parameters decreased at 3 months followed by a rebound increase at 6 and 12 months. SHBG levels were markedly reduced at 3 months (P = 0.006) and a wider range of dominant GH frequencies was present although GH AUC was not increased until 6 months, with an increase in GH pulse frequency but not amplitude. IGF-I levels were increased at both 3 and 12 months. In Group 3, pituitary-testicular suppression was not apparent, but GH levels increased with an increase in GH amplitude at 3 and 12 months. CONCLUSION: Oxandrolone transiently suppressed the pituitary-testicular axis and altered GH pulsatility. Testosterone increased GH via amplitude modulation.

[CJWolf]

DO NOT BRIDGE

THERE IS 0 NEED FOR YOU TO BRIDGE

WHY CAN'T PEOPLE JUST COME OFF A CYCLE AND RECOVER ALREADY

[CJWolf]

why are you using 100 mg/day

i seriously think you need to just calm down with the juice man ....

but hey, maybe next cycle you can do something like 200 mg/day winny

[Drenten]

Originally posted by Josh
and does the IP var suck ass?

I haven’t used any IP products (and never will), but from what I have heard, pretty much all their products suck.

Also, I think it was IP Anavar that had actually tested out to be Anadrol; not exactly what you would call a similar compound.

BTW – I bridge with TU. I get no liver toxicity, no HPTA suppression, and no muscle loss. What’s not to love?

[Massive1]

Another bridge option and less costly than anavar would be slin for 4weeks then clen/nyc 3weeks. Easier than it's cracked up to be, qiuet effective, and not suppressive of the htpa axis.

[CJWolf]

who needs a bridge after their first cycle ...

NO ONE

[Massive1]

Originally posted by CJWolf
who needs a bridge after their first cycle ...

NO ONE

true dat

[Drenten]

Originally posted by CJWolf
who needs a bridge after their first cycle ...

NO ONE

Yeah, I definitely agree with you on that.

[Josh]

k i was jw but thanx

[Governor]

Originally posted by Bull
I was not talking about HTPA, I was taking about liver toxic. Thanks anyway.

just becuase you edited your post, doesnt mean you werent originally talking about HTPA.

so you say HTPA but really mean liver toxicity??
Oh I think I got it now.

[Governor]

Originally posted by Drenten
I haven’t used any IP products (and never will), but from what I have heard, pretty much all their products suck.

Also, I think it was IP Anavar that had actually tested out to be Anadrol; not exactly what you would call a similar compound.

BTW – I bridge with TU. I get no liver toxicity, no HPTA suppression, and no muscle loss. What’s not to love?

what the hell is TU?

[Josh]

Originally posted by Governor
what the hell is TU?

andriol right?

[CJWolf]

yes, testosterone undecanoate